Effect of Lipid lowering Therapy and Regular Exercise on the Fibrinolytic System in Patients with Metabolic Syndrome

*Vorobyeva NV
Department Of Physical Education, Kursk State University, Russian Federation

*Corresponding Author:
Vorobyeva NV
Department Of Physical Education, Kursk State University, Russian Federation
Email:ilmedv1@yandex.ru

Published on: 2019-10-07

Abstract

At present, it has been established that in patients with a combination of the main components of the metabolic syndrome (arterial hypertension, dyslipidemia, abdominal obesity, insulin resistance), violations occur in many vital systems, including the hemostasis system. The effect of short term (8-week) course of combination of lipid-lowering therapy and dose-related physical loads on the parameters of the fibrinolysis system in patients with metabolic syndrome was studied. It was shown that treatment with a combination of fibrates with physical loads is accompanied by a decrease in the level of fibrinogen and acceleration of fibrinolysis. The use of statins as hypolipidemic agents was accompanied by a reduction in the level of fibrinogen compared with fibrates and activation of fibrinolysis. Obviously, exercise exacerbates the mechanisms of action of hypolipidemic drugs on fibrinogen synthesis and fibrinolysis processes, which causes a favorable effect of their combined use.

Keywords

Metabolic syndrome; Hemostasis; Statins; Fibrates; Physical activity

Introduction

At present, it has been established that in patients with a combination of the main components of the metabolic syndrome (arterial hypertension, dyslipidemia, abdominal obesity, insulin resistance), disorders develop in many vital systems [1,2], including in the hemostatic system [3]. It was found that with the metabolic syndrome, the thrombogenic potential of the blood can be greatly increased [4,5]. In these patients, thrombus formation was increased and fibrinolysis was reduced [6]. Moreover, at present, a high level of the inhibitor of the tissue activator of plasminogen type 1, which contributes to the reduction of fibrinolytic activity of the blood, is already considered to be the main component of the metabolic syndrome [7]. All this contributes to the development of cardiovascular diseases, thrombosis in persons with metabolic syndrome [8,9].

scroll up